公开(公告)号：US20190025294A1

公开(公告)日：2019-01-24

申请号：US15991572

申请日：2018-05-29

申请人： COMSATS University Islamabad

发明人： Akhtar Hayat ,  Muhammad Azhar Hayat Nawaz

IPC分类号： G01N33/52

CPC分类号： G01N33/523 ,  C12Q1/60 ,  G01N33/92 ,  G01N2400/18 ,  G01N2800/044

摘要： A method for colorimetric detection of cholesterol in a sample is disclosed. The method includes adding beta-cyclodextrin and cholesterol to a phenolphthalein indicator solution in the presence of a phosphate buffer solution to create a solution medium and quantifying the cholesterol as a function of a complexed beta-cyclodextrin in the solution medium.

公开(公告)号：US20180143205A1

公开(公告)日：2018-05-24

申请号：US15570124

申请日：2016-04-12

申请人： NESTEC S.A.

发明人： Irina IRINCHEEVA ,  Jorg HAGER ,  Loic DAYON ,  Ornella COMINETTI

IPC分类号： G01N33/68 ,  G01N33/92 ,  G01N33/573 ,  G16H20/60 ,  A23L33/00

CPC分类号： G01N33/6893 ,  A23L33/30 ,  A23V2002/00 ,  C12Y304/21034 ,  G01N33/573 ,  G01N33/92 ,  G01N2333/4703 ,  G01N2333/775 ,  G01N2333/81 ,  G01N2333/811 ,  G01N2333/8121 ,  G01N2333/96455 ,  G01N2800/04 ,  G01N2800/044 ,  G01N2800/52 ,  G16H20/60

摘要： A method for predicting the degree of weight loss in a female subject attainable by applying one or more dietary interventions to a subject, said method comprising; determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z-dependent protease inhibitor and plasma serine protease inhibitor.

公开(公告)号：US20180122887A1

公开(公告)日：2018-05-03

申请号：US15815995

申请日：2017-11-17

申请人： uBiome, Inc.

发明人： Zachary Apte ,  Daniel Almonacid ,  Jessica Richman

IPC分类号： H01L27/32 ,  H01L51/52 ,  H01L51/00

CPC分类号： G16H10/40 ,  C12Q1/6883 ,  C12Q2600/112 ,  G01N2800/044 ,  G01N2800/32 ,  G06F19/3418 ,  G16B40/00 ,  G16B50/00 ,  G16H40/67 ,  G16H50/20 ,  H01L27/3211 ,  H01L27/322 ,  H01L27/3272 ,  H01L51/0097 ,  H01L51/5234 ,  H01L51/5265 ,  H01L51/5281 ,  H01L51/5284 ,  H01L2251/5338 ,  Y02A90/26

摘要： A method for at least one of characterizing, diagnosing, and treating a cardiovascular disease condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the cardiovascular disease condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the cardiovascular disease condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

公开(公告)号：US20180090552A1

公开(公告)日：2018-03-29

申请号：US15816041

申请日：2017-11-17

申请人： uBiome, Inc.

发明人： Zachary Apte ,  Daniel Almonacid ,  Jessica Richman

IPC分类号： H01L27/32 ,  H01L51/52 ,  H01L51/00

CPC分类号： G16H10/40 ,  C12Q1/6883 ,  C12Q2600/112 ,  G01N2800/044 ,  G01N2800/32 ,  G06F19/3418 ,  G16B40/00 ,  G16B50/00 ,  G16H50/20 ,  H01L27/3211 ,  H01L27/322 ,  H01L27/3272 ,  H01L51/0097 ,  H01L51/5234 ,  H01L51/5265 ,  H01L51/5281 ,  H01L51/5284 ,  H01L2251/5338 ,  Y02A90/26

摘要： A method for at least one of characterizing, diagnosing, and treating a cardiovascular disease condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the cardiovascular disease condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the cardiovascular disease condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

公开(公告)号：US20180088134A1

公开(公告)日：2018-03-29

申请号：US15558322

申请日：2015-12-23

申请人： Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH

发明人： Bertram Flehmig

IPC分类号： G01N33/74

CPC分类号： G01N33/74 ,  C07K14/5759 ,  G01N2800/044

摘要： The invention relates to a compilation of detection reagents, wherein the compilation comprises a first and a second detection reagent, wherein the first detection reagent binds non-mutated leptin with a first binding value, but does not bind mutated leptin or binds it with a maximum of 50% of the binding value of non-mutated leptin, and wherein the second detection reagent binds both mutated and non-mutated leptin with a second binding value. The invention furthermore relates to an in-vitro method for detecting mutated leptin and the use of a detection reagent.

公开(公告)号：US09915645B2

公开(公告)日：2018-03-13

申请号：US14153994

申请日：2014-01-13

申请人： True Health Diagnostics, LLC

发明人： Steve Varvel ,  Rebecca E. Caffrey ,  James V. Pottala

IPC分类号： A61K38/00 ,  G01N33/50 ,  G01N33/92

CPC分类号： G01N33/50 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/042 ,  G01N2800/044 ,  G01N2800/50

摘要： This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction. An increased AHB level at fasting baseline and an elevated glucose level of at least about 155 mg/dL at 30 minutes and/or 1 hour indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing clinically significant post-prandial hyperglycemia.

公开(公告)号：US20180038878A1

公开(公告)日：2018-02-08

申请号：US15720274

申请日：2017-09-29

申请人： SEKISUI MEDICAL CO., LTD.

发明人： Mitsuaki YAMAMOTO ,  Shoko YAMAMOTO ,  Mitsuhiro NAKAMURA ,  Kazunori SAITO

IPC分类号： G01N33/92 ,  C07F7/18 ,  C12Q1/44 ,  C12Q1/60

CPC分类号： G01N33/92 ,  C07F7/18 ,  C12Q1/44 ,  C12Q1/60 ,  C12Q1/61 ,  G01N2800/044

摘要： A method of lipid assay characterized by assaying the lipids contained in a blood component in the presence of an organic silicon compound. The method can cause specific conditions for direct methods while satisfying requirements such as no influence on precision of assay, no burden on assay apparatus, and easy availability.

公开(公告)号：US20180009903A1

公开(公告)日：2018-01-11

申请号：US15520285

申请日：2015-10-22

申请人： Katholieke Universiteit Leuven Ku Leuven Research & Development

发明人： Henri Roger Lijnen ,  Dries Bauters

IPC分类号： C07K16/40

CPC分类号： C07K16/40 ,  C07K2317/76 ,  C12Q1/37 ,  C12Y304/24 ,  G01N2333/96419 ,  G01N2800/044

摘要： The invention relates to the field of obesity and related metabolic diseases. More specifically, the invention relates to methods of reducing aggrecanase activity or antigen in mammals in order to enhance brown adipose tissue (BAT) development, to promote conversion of white adipose tissue (WAT) into BAT in vivo, and to limit triglyceride accumulation and steatosis in the liver. The invention also relates to a strategy of neutralization or depletion of ADAMTS5 as a strategy to inhibit adipogenesis and more specifically, the invention relates to a method of reducing aggracanase-2 (ADAMTS5, A Disintegrin and Metalloproteinase with Thrombospondin motif 1; member 5) antigen and/or activity in mammals in order to impair differentiation of precursor cells into mature adipocytes (i.e., adipogenesis).

公开(公告)号：US20170329923A1

公开(公告)日：2017-11-16

申请号：US15664067

申请日：2017-07-31

申请人： uBiome, Inc.

发明人： Zachary Apte ,  Daniel Almonacid ,  Jessica Richman

IPC分类号： G06F19/00 ,  C12Q1/68 ,  G06F19/24 ,  G06F19/28

CPC分类号： G16H10/40 ,  C12Q1/6883 ,  C12Q2600/112 ,  G01N2800/044 ,  G01N2800/32 ,  G06F19/3418 ,  G16B40/00 ,  G16B50/00 ,  G16H40/67 ,  G16H50/20 ,  H01L27/3211 ,  H01L27/322 ,  H01L27/3272 ,  H01L51/0097 ,  H01L51/5234 ,  H01L51/5265 ,  H01L51/5281 ,  H01L51/5284 ,  H01L2251/5338 ,  Y02A90/26

摘要： A method for at least one of characterizing, diagnosing, and treating a cardiovascular disease condition in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the cardiovascular disease condition based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the cardiovascular disease condition; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

公开(公告)号：US09775879B2

公开(公告)日：2017-10-03

申请号：US14888343

申请日：2014-04-30

申请人： Korea University Research and Business Foundation

发明人： Je Sang Ko ,  Jeong-Han Kim

IPC分类号： A61K38/17 ,  C12Q1/68 ,  G01N33/50 ,  C12N5/077

CPC分类号： A61K38/17 ,  C12N5/0653 ,  C12N2501/998 ,  C12N2506/1346 ,  C12N2506/1353 ,  C12Q1/686 ,  G01N33/502 ,  G01N2500/00 ,  G01N2500/10 ,  G01N2800/042 ,  G01N2800/044

摘要： The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.